- CEO
- Jin Fang Lou
- Full Time Employees
- 1,412
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hangzhou China
- IPO Date
- Dec 20, 2021
- Business
- Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. is a comprehensive pharmaceutical contract research organization and contract development and manufacturing organization providing integrated drug discovery, formulation development, clinical research, and commercialization services to domestic and international pharmaceutical and biotechnology enterprises. Founded in 2011 and headquartered in Hangzhou, Zhejiang Province, China, the company operates modern research and development laboratories, bioanalytical testing facilities, and Good Manufacturing Practice compliant production sites across China. Hangzhou Bio-Sincerity Pharma-Tech structures its business into four principal operational divisions: Pharmaceutical Research and Development Services, Clinical Operations and Bioanalytical Services, CDMO Manufacturing Services, and Proprietary Technology Transfer and Commercialization. The company's core products and service offerings include preclinical pharmaceutical research, encompassing active pharmaceutical ingredient chemical synthesis, synthetic process optimization, formulation design, analytical chemistry, impurity characterization, and stability testing; clinical trial and bioequivalence services, covering Phase I to IV clinical trial management, medical writing, trial monitoring, regulatory filing, data management, biostatistical analysis, and high-throughput bioanalytical pharmacokinetic and pharmacodynamic assays; generic drug consistency evaluation services, comprising comparative dissolution profile studies, pharmaceutical equivalence testing, and regulatory submission documentation; CDMO pilot and commercial production, providing pilot-scale formulation manufacturing, sterile injectable preparation, oral solid dosage production, and commercial active pharmaceutical ingredient manufacturing through dedicated subsidiaries including Zhejiang Saimo Pharmaceutical Co., Ltd.; and proprietary drug research and technology transfer, involving the independent development, out-licensing, and collaborative commercialization of complex generic formulations, modified-release pharmaceuticals, and innovative small molecules with associated milestone and royalty-sharing rights. In recent developments, the company has expanded its integrated CDMO operational capacity through the ramp-up of commercial-scale GMP manufacturing bases, augmented its proprietary research pipeline with an increased focus on complex formulation delivery systems, specialized inhalation therapies, and peptide platforms, strengthened strategic co-development partnerships with major domestic pharmaceutical manufacturers, and upgraded its high-throughput bioanalysis and automated clinical data infrastructure to support cross-regional drug approvals.